Analysis of “Performance of an Automated Insulin Delivery System in People Living With Type 2 Diabetes and Insulin Resistance: First Real-World Evidence in 26,427 Users”
Authors' conclusion
Despite limitations in baseline data and clinical parameters, the findings reinforce AID as an effective and scalable therapy for insulin-requiring T2D.
Study context
- Population
- Users of the MiniMed 780G system with T2D across 73 countries, categorized into four phenotypically distinct cohorts
- Participants
- 26,427 users
- Outcome
- Glycemic outcomes
Methodological details73 countries, Limitations in baseline data and clinical parameters
- 73 countries
- Limitations in baseline data and clinical parameters
Main finding
As reported in the abstract
- Consistent glycemic improvements across the four cohorts
Original publication
Analysis of “Performance of an Automated Insulin Delivery System in People Living With Type 2 Diabetes and Insulin Resistance: First Real-World Evidence in 26,427 Users”. J Diabetes Sci Technol. Published 16 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →